2024 Amyloidosis Forum Annual Meeting

October 23, 2024 | FDA White Oak Campus | Zoom

Participants including clinicians, researchers, FDA and global health authorities, industry partners, patients, and the Amyloidosis Research Consortium (ARC) will detail and highlight the advancements cultivated by Amyloidosis Forum working groups and outline goals and touchstones for future programs and research.

Public Private Partnership with FDA

Register

We are excited to have you join us either in-person at the FDA White Oak campus in Silver Spring, MD or online via Zoom! Please click the button below to register for our in-person meeting or the Zoom broadcast. We ask any sponsor groups to register via their organizational representative.

Faculty

https://amyloidosisforum.org/wp-content/uploads/2023/05/Isabelle-Lousada.jpeg
Isabelle Lousada
Host & Moderator
BIO+
https://amyloidosisforum.org/wp-content/uploads/2023/05/Kristen-Hsu.jpeg
Kristen Hsu
Host & Moderator
BIO+

Working Groups

https://amyloidosisforum.org/wp-content/uploads/2023/05/Ahmad-Masri.png
Ahmad Masri, MD, MS
Co-Chair, Imaging Standardization Working Group
BIO+
https://amyloidosisforum.org/wp-content/uploads/2023/05/Angela-Dispenzieri.png
Angela Dispenzieri, MD
Chair, Endpoints
Working Group

BIO+
https://amyloidosisforum.org/wp-content/uploads/2024/06/Ashutosh-Wechalekar.jpg
Ashutosh Wechalekar, MD, FRCP, FRCPath, DM
Co-Chair, Prognostic Factors Working Group
https://amyloidosisforum.org/wp-content/uploads/2024/06/Daniel-Judge.png
Daniel Judge, MD, FACC, FHFSA
Co-Chair, Endpoints Working Group
BIO+
https://amyloidosisforum.org/wp-content/uploads/2023/05/James-Signorovich.png
James Signorovich, PhD
Chair, Federated Analytics Working Group
https://amyloidosisforum.org/wp-content/uploads/2023/05/Mat-Maurer-3.png
Mathew S. Maurer,
MD
Chair, Prognostic Factors Working Group
BIO+
https://amyloidosisforum.org/wp-content/uploads/2024/06/Phaedra-Johnson.png
Phaedra Johnson, MS
Co-Chair, Federated Analytics Working Group
https://amyloidosisforum.org/wp-content/uploads/2023/05/Sharmila-Dorbala.png
Sharmila Dorbala, MD, MPH, MASNC
Chair, Imaging Standardization Working Group

Agenda

(Draft Agenda To Come)

How We Work

The Amyloidosis Forum has established a collaborative framework with appropriate stakeholders, including government, academic, scientific, patient, and industry organizations, to foster scientific collaborations. The Forum convenes regular meetings and has defined both workstreams and working groups to focus on key areas. The Forum is committed to publishing the outcomes from these initiatives.

Thank You to our Supporters

Gold

https://amyloidosisforum.org/wp-content/uploads/2024/06/Alexion-Gold.png
https://amyloidosisforum.org/wp-content/uploads/2024/06/Alnylam-Gold.png
https://amyloidosisforum.org/wp-content/uploads/2024/06/AZ-and-Ionis-Gold.png
https://amyloidosisforum.org/wp-content/uploads/2024/06/BridgeBio-Gold.png
https://amyloidosisforum.org/wp-content/uploads/2024/06/Intellia-Gold.png
https://amyloidosisforum.org/wp-content/uploads/2024/06/Novo-Nordisk-Gold.png
https://amyloidosisforum.org/wp-content/uploads/2024/06/Prothena-Gold.png

Bronze

https://amyloidosisforum.org/wp-content/uploads/2024/06/Abbvie-Bronze.png
https://amyloidosisforum.org/wp-content/uploads/2024/06/Attralus-Bronze.png
https://amyloidosisforum.org/wp-content/uploads/2024/06/Pfizer-Bronze.png
https://amyloidosisforum.org/wp-content/uploads/2024/06/Protego-Bronze.png

About the Fourm

In 2019, the Amyloidosis Research Consortium established a public private partnership with the FDA, named the Amyloidosis Forum with the goal of bringing together the entire amyloidosis community to identify and bridge scientific gaps that are acting as barriers to drug discovery and development for the treatment of amyloidosis. The Forum has held a number of meetings over the past few years and have several workstreams currently ongoing, including work to develop a multidomain composite endpoint, evaluating the performance of key biomarkers as surrogate endpoints, and establishing pathways for the development of imaging measures to serve as endpoints in clinical trials for AL and ATTR amyloidosis. The work through the Amyloidosis Forum is a collaborative effort led by clinicians, researchers, patients, regulators across the US, Europe, and UK, and industry.

Learn More

 

Anonymous Reporting

The Amyloidosis Research Consortium (ARC) is dedicated to providing a harassment-free conference. To read our Safety Plan detailing our commitment or submit a secure, anonymous report of an incident, please use the corresponding buttons below.

Safety Plan Reporting Form